Syndax collaborates with Incyte to develop monoclonal antibody
The antibody will be developed to treat chronic graft-versus-host disease and other immune-mediated diseases.
News
Pfizer starts Phase II/III trial of oral antiviral for Covid-19 prevention
The trial will have 2,660 healthy adult subjects who are living in the same household...
Hikma to acquire Custopharm for $425m to boost US injectables business
With the takeover, Hikma will add 13 approved products and additional products in the pipeline...
GeNeuro announces agreement to assess W-ENV and long-Covid syndromes
The link between W-ENV and long-Covid will be analysed to use GeNeuro’s temelimab in affected...
WHO recommends use of Regeneron’s Covid-19 antibody drug cocktail
The development is based on a British trial in 9,000 subjects, in which the antibody...
AstraZeneca and VaxEquity partner to advance RNA therapeutics
VaxEquity will receive development, approval and sales-based milestone payments of up to $195m from AstraZeneca.
Novavax and SII seek WHO emergency use listing for Covid-19 vaccine
WHO authorisation is a prerequisite to supply the vaccine to several countries that are part of the COVAX Facility.
Tonix and Columbia University to develop specialised Covid-19 vaccines
The alliance plans to isolate therapeutically significant fully human neutralising monoclonal antibodies against Covid-19.
Immunic signs agreement to in-license assets to treat viral infections
A combination of DHODH inhibitor, IMU-838 and N4-hydroxycytidine offered a decline in viral RNA to undetectable levels.
AbCellera and Everest enter deal to discover antibody therapies
Everest will make research, milestone and royalty payments to AbCellera for the products developed through the collaboration.
FDA approves Pfizer Covid vaccine booster shot for older population
A third vaccine dose is intended for people at high risk and those prone to institutional or occupational exposure to the virus.
